SummitTX Capital L.P. Buys Shares of 13,550 Halozyme Therapeutics, Inc. $HALO

Posted by Geri Gentry on Jul 31st, 2026

SummitTX Capital L.P. purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 13,550 shares of the biopharmaceutical company’s stock, valued at approximately $876,000.

A number of other institutional investors have also made changes to their positions in HALO. Measured Wealth Private Client Group LLC increased its holdings in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the last quarter. Harbour Investments Inc. raised its position in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 372 shares during the period. Clearstead Advisors LLC boosted its stake in Halozyme Therapeutics by 64.8% during the 4th quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 331 shares during the last quarter. Finally, Wexford Capital LP acquired a new position in Halozyme Therapeutics during the third quarter valued at approximately $70,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. UBS Group reiterated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

View Our Latest Report on HALO

Halozyme Therapeutics Stock Up 0.0%

Shares of HALO stock opened at $83.30 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $58.53 and a 52-week high of $84.44. The stock has a market cap of $9.88 billion, a price-to-earnings ratio of 29.96, a PEG ratio of 0.35 and a beta of 0.84. The firm’s 50-day moving average is $74.24 and its 200-day moving average is $70.85. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. During the same quarter last year, the company posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This trade represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 72,477 shares of company stock valued at $5,102,643. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.